# Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Study · id `cardio:ct-nct02946632` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02946632](<https://clinicaltrials.gov/study/NCT02946632>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02946632

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

## Technical summary

Registry record NCT02946632. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT02946632, source copy `cardio:ctgov-nct02946632-2016-10-27`, retrieved 2026-11-18)
- Start date: 2016-12 (registry gives no type) (ClinicalTrials.gov record NCT02946632, source copy `cardio:ctgov-nct02946632-2016-10-27`, retrieved 2026-11-18)
- Primary completion: 2019-12 (anticipated) (ClinicalTrials.gov record NCT02946632, source copy `cardio:ctgov-nct02946632-2016-10-27`, retrieved 2026-11-18)
- Completion: 2019-12 (anticipated) (ClinicalTrials.gov record NCT02946632, source copy `cardio:ctgov-nct02946632-2016-10-27`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT02946632, source copy `cardio:ctgov-nct02946632-2016-10-27`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02946632-2016-10-27`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
- Condition: Diabetes Mellitus, Type II
- Intervention (Drug): triple combination therapy
- Intervention (Drug): Stepwise add-on therapy
- Lead sponsor: Korea University Anam Hospital
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Korea University Anam Hospital (`cardio:org-korea-university-anam-hospital`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial (`cardio:pubmed-38853720`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c5eb566dbc3ae3e2ce6202ce2704e2fe908ea958abc817ffffaa30a57d01ed5e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
